Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2024Neuro-OncologyOpen Access

NFS-27. Selumetinib for Symptomatic, Inoperable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Single-Institution Experience

View Full Paper
Ask AI
Bookmark
Share

Authors

FVFelisa Vázquez-GómezHospital Infantil Universitario Niño JesúsMPMarta Pérez‐SomarribaHospital Sant Joan de Déu BarcelonaSCSerafin CastellanoHospital Infantil Universitario Niño Jesús

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vázquez-Gómez et al. (2024) studied this question.

synapsesocial.com/papers/68e643e9b6db6435875d5a70https://doi.org/10.1093/neuonc/noae064.585
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selumetinib in the treatment of plexiform neurofibromas in neurofibromatosis type 1: a 6-year prospective case series with review of the literature2026
  2. 2Management of selumetinib-associated toxicity in children with neurofibromatosis type 1 and plexiform neurofibromas2025
  3. 3Real-world experience with selumetinib in children with neurofibromatosis type 1: a multicentric retrospective study2025 · 5 citations
  4. 4Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management2024 · 22 citations
  5. 5Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management2024 · 2 citations